advertising
-
1
Rice JB, Desai U, Cummings AK, et al.: Burden of DFUs for Medicare and private insurers. Diabetes Care 37: 651, 2014.
-
2
American Diabetes Association: Economic costs of diabetes in the U.S. in 2012. Diabetes Care 36: 1033, 2013.
-
3
Heron M: Deaths: leading causes for 2017. Natl Vital Stat Rep 68: 1, 2019.
-
4
Lepäntalo M, Apelqvist J, Setacci C, et al.: Chapter V: diabetic foot. Eur J Vasc Endovasc 42 (suppl): S60, 2011.
-
5
American Diabetes Association: Statistics about diabetes. Available at: https://www.diabetes.org/resources/statistics/statistics-about-diabetes. Accessed January 10, 2020.
-
6
Margolis DJ, Kantor J, Berlin JA Healing of diabetic neuropathic foot ulcers receiving standard treatment. A meta-analysis. Diabetes Care 22: 692, 1999.
-
7
Duzgun AP, Satır HZ, Ozozan O, et al.: Effect of hyperbaric oxygen therapy on healing of diabetic foot ulcers. J Foot Ankle Surg 47: 515, 2008.
-
8
Santema KTB, Stoekenbroek RM, Koelemay MJW, et al.: Hyperbaric oxygen therapy in the treatment of ischemic lower-extremity ulcers in patients with diabetes: results of the DAMO2CLES Multicenter Randomized Clinical Trial. Diabetes Care 41: 112, 2017.
-
9
Löndahl M, Katzman P, Nilsson A, et al.: Hyperbaric oxygen therapy facilitates healing of chronic foot ulcers in patients with diabetes. Diabetes Care 33: 998, 2010.
-
10
Blume PA, Walters J, Payne W, et al.: Comparison of negative pressure wound therapy using vacuum-assisted closure with advanced moist wound therapy in the treatment of diabetic foot ulcers: a multicenter randomized controlled trial. Diabetes Care 31: 631, 2008.
-
11
Gordillo GM, Roy S, Khanna S, et al.: Topical oxygen therapy induces vascular endothelial growth factor expression and improves closure of clinically presented chronic wounds. Clin Exp Pharmacol Physiol 35: 957, 2008.
-
12
Fries RB, Wallace WA, Roy S, et al.. Dermal excisional wound healing in pigs following treatment with topically applied pure oxygen. Mutat Res 579: 172, 2005.
-
13
Frykberg RG, Franks PJ, Edmonds M, et al.: A multinational, multicenter, randomized, double-blinded, placebo-controlled trial to evaluate the efficacy of cyclical topical wound oxygen therapy (TWO2) in the treatment of chronic diabetic foot ulcers: the TWO2 study. Diabetes Care 43: 616, 2020.
-
14
Copeland K, Purvis AR: A retrospective chart review of chronic wound patients treated with topical oxygen therapy. Adv Wound Care (New Rochelle) 6: 143, 2917.
-
15
Cronjé FJ: Oxygen therapy and wound healing—topical oxygen is not hyperbaric oxygen therapy. S Afr Med J 9: 840, 2005.
-
16
Mutluoglu M, Cakkalkurt A, Uzun G, et al.: Topical oxygen for chronic wounds: a PRO/CON debate. J Am Coll Clin Wound Spec 5: 61, 2013.
-
17
Unger PG: Low-frequency, noncontact, nonthermal ultrasound therapy: a review of the literature. Ostomy Wound Manage 54: 57, 2008.
-
18
Driver VR, Yao M, Miller CJ: Noncontact low-frequency ultrasound therapy in the treatment of chronic wounds: a meta-analysis. Wound Repair Regen 19: 475, 2011.
-
19
Padberg FT, Black TL, Thompson PN, et al.. Transcutaneous oxygen (TcPO2) estimates probability of healing in the ischemic extremity. J Surg Res 60: 365, 1996.
-
20
Ennis WJ, Valdes W, Gainer M, et al.: Evaluation of clinical effectiveness of MIST ultrasound therapy for the healing of chronic wounds. Adv Skin Wound Care 19: 437, 2006.
-
21
Ennis WJ, Foremann P, Mozen N, et al.: Ultrasound therapy for recalcitrant diabetic foot ulcers: results of a randomized, double-blind, controlled, multicenter study. Ostomy Wound Manage 51: 24, 2005.
-
22
Niederauer MQ, Michalek JE, Armstrong DG. A prospective, randomized, double-blind multicenter study comparing continuous diffusion of oxygen therapy to sham therapy in the treatment of diabetic foot ulcers. J Diabetes Sci Technol 11: 883, 2017.
-
23
Brem H, Tomic-Canic M: Cellular and molecular basis of wound healing in diabetes. J Clin Invest 117: 1219, 2007.
Treatment of Nonhealing Diabetic Foot Wounds with Vaporous Hyperoxia Therapy in Conjunction with Standard Wound Care
Search for other papers by Dustin Kruse in
Current site
Google Scholar
PubMed
Search for other papers by Kenneth Morgan in
Current site
Google Scholar
PubMed
Search for other papers by Jeremy Christensen in
Current site
Google Scholar
PubMed
Search for other papers by Brian S. Derner in
Current site
Google Scholar
PubMed
Search for other papers by Brett Sachs in
Current site
Google Scholar
PubMed
Background: Vaporous hyperoxia therapy (VHT), a patented US Food and Drug Administration 510 (k)–cleared technology, is an adjunct therapy used in conjunction with standard wound care (SWC). Vaporous hyperoxia therapy is said to improve the health of wounded tissue by administering a low-frequency, noncontact, nonthermal, ionic, antimicrobial hydrating mist alternating with concentrated topical oxygen therapy.
Methods: Vaporous hyperoxia therapy was used to treat 36 subjects with chronic diabetic foot ulcers (DFUs) that were previously treated unsuccessfully with SWC. The average age of DFUs in the study was 11 months and the average size was over 3 cm2. Wounds were Wagner grade 2 or 3 and most commonly on the plantar surface around the midfoot. Treatment consisted of twice-weekly applications of VHT and wound debridement. Subjects were followed to wound closure, 20 weeks, or 40 treatments, whichever came first.
Results: The combination of SWC and VHT in the group that met and maintained compliance throughout the study period achieved an 83% DFU closure rate within a 20-week period. The average time for DFU closure in this study was 9.4 weeks.
Conclusions: Historical analysis of SWC shows a 30.9% healing rate of all wounds, not differentiating chronic wounds. Accordingly, SWC/VHT increases chronic diabetic foot ulcer healing rates by 2.85 times compared with SWC alone. The purpose of this study was two-fold: first, to observe the effect of VHT on healing rates and time to healing in previously nonhealing DFUs; and second, to compare VHT with SWC, topical oxygen therapy, hyperbaric oxygen therapy, and ultrasound therapy.
advertising
advertising
